Product Information

ETRAVIRINE 200 MG TABLET is a generic product labeled by Leading Pharma, LLC, priced at $9.2368 per EA under NDC 69315028606. Its NADAC has been published 223 times since Aug 10, 2022.

FDA first approved this application on Apr 13, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ETRAVIRINE 200 MG TABLET

ETRAVIRINE
$9.2368per EA

Strength

200 mg/1

NDC

69315028606

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

ETRAVIRINE

Approval Type

Generic (ANDA)

FDA Application

ANDA215402

FDA Approved

4/13/2022

TE Code

AB

On Market Since

6/5/2022

Pharmacological Classes

Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C9 Inhibitors
Cytochrome P450 3A Inducers
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Analog
Non-Nucleoside Reverse Transcriptase Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for ETRAVIRINE 200 MG TABLET has been published 223 times since Aug 10, 2022, and over the history we have for it it has declined 47.8%. The table below summarizes its recorded NADAC range and movement.

Current price$9.2368 per EA
All-time high$17.7091 (Mar 15, 2023)
All-time low$9.2368 (Oct 21, 2026)
52-week high$11.7118
52-week low$9.2368
Median price$13.0345
Average price$13.8113
Largest weekly change+13.4% (Oct 23, 2024)
Weeks tracked223
Tracking sinceAug 10, 2022

Price History

1W

0.0%

1M

-7.1%

3M

-17.8%

6M

-18.4%

1Y

-18.7%

3Y

-42.4%

5Y

N/A

All

-47.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ETRAVIRINE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ETRAVIRINE 200 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ETRAVIRINE 200 MG TABLET, manufactured by Leading Pharma, LLC, is $9.2368 per EA (NDC 69315028606), effective Nov 11, 2026.

How has the price of ETRAVIRINE 200 MG TABLET changed over time?

Over the history we have for it, the NADAC for ETRAVIRINE 200 MG TABLET has declined 47.8%. It has been tracked across 223 weekly CMS publications since Aug 10, 2022.

What are the highest and lowest recorded NADAC prices for ETRAVIRINE 200 MG TABLET?

Since Aug 10, 2022, the NADAC for ETRAVIRINE 200 MG TABLET has ranged from a low of $9.2368 (Oct 21, 2026) to a high of $17.7091 (Mar 15, 2023), with a median of $13.0345 per EA.

Are there cheaper alternatives to ETRAVIRINE 200 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of ETRAVIRINE 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures ETRAVIRINE 200 MG TABLET?

ETRAVIRINE 200 MG TABLET (NDC 69315028606) is labeled by Leading Pharma, LLC, and CMS classifies it as a generic product.